Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.61 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20697830 | 1.00 | TAS1R3 (0.61) | TAS1R3TAS1R1KMT2AMEN1TDP1 | |
| SCHEMBL19083996 | 0.86 | TAS1R3 (0.64) | TAS1R3TAS1R1L3MBTL1PDE4APDE4B | |
| SCHEMBL23118386 | 0.86 | KMT2A (0.54) | TAS1R3TAS1R1KMT2AMEN1TDP1 | |
| SCHEMBL20697674 | 0.80 | KMT2A (0.57) | TAS1R3TAS1R1KMT2AMEN1TDP1 | |
| SCHEMBL19083822 | 0.80 | KMT2A (0.57) | TAS1R3TAS1R1KMT2AMEN1TDP1 | |
| SCHEMBL4202902 | 0.76 | TAS1R3 (1.00) | TAS1R3TAS1R1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL8368230 | 0.74 | TAS1R3 (0.72) | TAS1R3TAS1R1KMT2AL3MBTL1 | |
| SCHEMBL19083995 | 0.72 | TAS1R3 (0.62) | TAS1R3TAS1R1PDE4APDE4BPDE4C | |
| SCHEMBL8368815 | 0.71 | TAS1R3 (0.63) | TAS1R3TAS1R1KMT2AL3MBTL1 | |
| SCHEMBL13525007 | 0.71 | L3MBTL1 (0.71) | TAS1R3TAS1R1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | TAS1R3 2742/4885TAS1R1 2598/4885KMT2A 1836/4885 |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | TAS1R3 2742/4885TAS1R1 2598/4885KMT2A 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.